Herein, we demonstrated that SOX9 enhanced drug resistance in BCL2‐overexpressing DLBCL via a novel transcription factor, IRF4, by mediating BCL2‐induced SOX9 transcription. Here, SOX9 is linked to diffuse large B-cell lymphoma.